Multicentric evaluation of heparinase on aPTT, thrombin clotting time and a new PT reagent based on recombinant human tissue factor

Blood Coagulation and Fibrinolysis

Volumn 7, Issue 4, 1996, Pages 453-458

  Harenberg, J ^a   Reichel, Th ^a   Malsch, R ^a   Hirsh, J ^b   Rustagi, P ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b HAMILTON HEALTH SCIENCES   (Canada)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

anticoagulation; heparin; Heparinase; oral anticoagulants; thrombosis

Indexed keywords

COUMARIN; HEPARIN; HEPARIN LYASE; HEPZYME; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; HUMAN; MAJOR CLINICAL STUDY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBIN TIME;

EID: 0029768032     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199606000-00004     Document Type: Article

References (13)

1. Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-1574.
2. Hirsh J, Levine MN. Low molecular weight heparin-review article. Blood 1992; 79: 1-17.
3. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med 1992; 326: 975-982.
4. van den Besselaar AMHP, Meeuwisse-Braun J, Bertina RM. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex vivo heparin samples. Tbromb Haemostasis 1990; 63: 16-23.
5. Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287: 324-327.
6. Harenberg J, Giese Ch, Knödler A, Zimmermann R. Comparative study on a new one-stage clotting assay for heparin and its low molecular weight derivatives. Haemostasts 1989; 19: 13-20.
7. van den Besselaar AMHP, Meeuwisse-Braun J. Enzymatic elimination of heparin from plasma for activated partial thromboplastin time and prothrombin time testing. Blood Coag Fibrinol 1993; 4: 635-638.
8. Linhardt RJ, Grant A, Cooney CL, Larger R. Differential anticoagulant activity of heparin fragments prepared using microbial heparinase. J Biol Chem 1982; 257: 7310-7313.
9. Linhardt RJ, Fitzgerald GL, Cooney CL, Langer R. Mode of action of heparin lyase on heparin. Biochem Biophys Acta 1981; 702: 197-203.
10. Galliher RM, Cooney CL, Langer R, Linhardt RJ. Heparinase production by Flavobacterium heparinum. J Appl Environ Microbiol 1981; 42: 360-365.
11. Hutt ED, Kingdon HS. Use of heparinase to eliminate heparin inhibition in routine coagulation assays. J Lab Clin Med 1972; 79: 1027-1034.
12. Baugh RF, Deemar KA, Zimmermann JJ. Heparinase in the activated clotting time assay: monitoring heparin independent alterations in coagulation function. Anesthesia Analgesia 1992; 72: 201-205.
13. Kolde HJ, Hawkins P, Tejidor L, Denzler B, Ramirez I. Properties of a new thromboplastin reagent based on recombinant tissue factor and synthetic phospholipids. Klin Lab 1993; 39: 767-776.